Valganciclovir (VALGANCICLOVIR HYDROCHLORIDE)
Valganciclovir (VALGANCICLOVIR HYDROCHLORIDE) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Valganciclovir; Generic name: VALGANCICLOVIR HYDROCHLORIDE; Manufacturer: American Health Packaging.
| Brand name | Valganciclovir |
|---|---|
| Generic name | VALGANCICLOVIR HYDROCHLORIDE |
| Manufacturer | American Health Packaging |
| Used for | 1 INDICATIONS AND USAGE Valganciclovir is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients (1.1) Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk. Pediatric Patients (1.2) Prevention of CMV disease in kidney and heart transplant patients at high risk. 1.1 Adult Patients Treatment of Cytomegalovirus (CMV) Retinitis: Valganciclovir for oral solution is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) [see Clinical Studies (14.1) ]. Prevention of CMV Dis |
| Dosage | 2 DOSAGE AND ADMINISTRATION Adult Dosage (2.2) Treatment of CMV retinitis Induction: 900 mg (two 450 mg tablets) twice a day for 21 days Maintenance: 900 mg (two 450 mg tablets) once a day Prevention of CMV disease in heart or kidney-pancreas transplant patients 900 mg (two 450 mg tablets) once a day within 10 days of transplantation until 100 days post-transplantation Prevention of CMV disease in kidney transplant patients 900 mg (two 450 mg tablets) once a day within 10 days of transplantation |
| Warnings | Hematologic Toxicity: Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, and bone marrow failure including aplastic anemia have been reported in patients treated with valganciclovir for oral solution [see Warnings and Precautions (5.1) ]. Impairment of Fertility: Based on animal data and limited human data, valganciclovir for oral solution may cause temporary or permanent inhibition of spermatogenesis in males and suppression of fertility in females [see Warnings and Precaut |
| Active ingredient(s) | VALGANCICLOVIR HYDROCHLORIDE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e30509f-add6-43c8-9e1d-e10c55a207e6 |